Intercept Pharmaceuticals (ICPT): Phase 2 Data Anticipated Mid-Year - JMP
Tweet Send to a Friend
JMP Securities analyst. Liisa Bayko, reiterated her Market Outperform rating on shares of Intercept Pharmaceuticals (NASDAQ: ICPT) in advance ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


